Garde Capital’s Champions Oncology CSBR Stock Holding History

Garde Capital’s Portfolio CSBR Stock Details CSBR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1	Closed	-$8	–	375
2025 Q2	$8	Hold	1	–	–	﹤0.01%	835
2025 Q1	$9	Buy	+1	New	+$10	﹤0.01%	825

Other funds holding CSBR

BMC

Battery Management Corp Boston, Massachusetts $426M AUM 21.5% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Garde Capital's CSBR Position: Q3 2025 in Review

Garde Capital sold out of Champions Oncology (CSBR) in Q3 2025, closing a stake of 1 share — an estimated $8 sold.

Garde Capital first reported a position in CSBR in Q1 2025 and held it in 2 quarters. The position peaked at $9 in Q1 2025. 27 funds tracked by Wall St. Rank hold CSBR as of Q3 2025.

Garde Capital reported no remaining Champions Oncology position as of Q3 2025 after selling out during the quarter.
Garde Capital sold 1 Champions Oncology share in Q3 2025, an estimated $8.
Garde Capital first reported a position in Champions Oncology in Q1 2025 and held it in 2 quarters.
Garde Capital's Champions Oncology position peaked at $9 in Q1 2025.
27 funds tracked by Wall St. Rank held Champions Oncology as of Q3 2025.

Based on Garde Capital's 13F filing for Q3 2025, filed 16 Dec 2025.